Netherlands First Proton Therapy Center Selects RayStation
News Jun 21, 2016
RayStation has been selected as the treatment planning solution for the Holland Particle Therapy Centre (HollandPTC), the first proton therapy center to be established in the Netherlands. The facility will open in August 2017 and expects to treat around 600 patients per year using the Varian ProBeam® System. The new center will mean that patients in the Netherlands no longer have to travel abroad to receive proton therapy.
Outstanding capabilities for proton planning, based on proven, innovative technology, make RayStation the solution of choice for many of the leading proton therapy centers worldwide. HollandPTC selected RayStation over other market-leading alternatives following an extensive tender process. RayStation received the highest assessment in a number of key areas, including adaptive therapy, connectivity, automation and scripting, user experience, and plan optimization.
Next-generation plan optimization was an important area for HollandPTC, and RayStation’s multi-criteria optimization made the system a clear leader. Delivery of the treatment planning solution will begin in the third quarter of 2016, with functionality including pencil beam scanning, adaptive therapy, radiobiology and multi-criteria optimization. The agreement includes both clinical and research licenses. As well as supporting world-class patient care, RayStation will play an important role as a platform for pioneering research.
The research partnership will cover areas such as adaptive therapy (online and offline), automated multi-criteria optimization, range verification and radiobiologically guided therapies. Martijn Eenink, Medical Physicist at HollandPTC and Leiden University Medical Center, says: “We are excited about the opportunities RayStation offers for delivering patient care. RayStation’s multi-criteria optimization will facilitate the production of treatment plans of the highest quality. The integrated support for image-guided proton therapy will allow us to easily adapt these plans to changes in patient anatomy during the course of treatment, thereby enhancing treatment accuracy.”
Johan Löf, CEO of RaySearch Laboratories, says: “Proton therapy is an important area of focus for RaySearch, and we have designed RayStation to deliver on its therapeutic possibilities. We have also ensured that RayStation can be used to create treatment plans for all relevant proton therapy machines on the market, and this of course includes the Varian ProBeam. I’m excited about the opportunity to both support clinical excellence at HollandPTC and drive development through this partnership.”
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018